AKT1 (NM_005163) Human Recombinant Protein
SKU
TP320257
Recombinant protein of human v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 1, 20 µg
$737.00
In Stock*
Specifications
| Product Data | |
| Species | Human |
|---|---|
| Expression Host | HEK293 |
| Expression cDNA Clone or AA Sequence | |
| Tag | C-Myc/DDK |
| Predicted MW | 55.5 kDa |
| Concentration | >0.05 µg/µL as determined by microplate BCA method |
| Purity | > 80% as determined by SDS-PAGE and Coomassie blue staining |
| Buffer | 25 mM Tris-HCl, 100 mM glycine, pH 7.3, 10% glycerol |
| Preparation | Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. |
| Note | For testing in cell culture applications, please filter before use. Note that you may experience some loss of protein during the filtration process. |
| Storage | Store at -80°C. |
| Stability | Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. |
| Shipping | Dry Ice |
| Reference Data | |
| RefSeq | NP_005154 |
| Locus ID | 207 |
| UniProt ID | P31749 |
| Cytogenetics | 14q32.33 |
| RefSeq Size | 3008 |
| RefSeq ORF | 1440 |
| Synonyms | AKT; PKB; PKB-ALPHA; PRKBA; RAC; RAC-ALPHA |
| Summary | This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. provided by RefSeq, Jul 2020 |
| Protein Categories | Cancer: Brain and CNS, Cancer: Gynecologic, Cytokines, Enzyme: Kinases, Growth Factors, Intracellular Proteins |
| Protein Families | Druggable Genome, ES Cell Differentiation/IPS, Protein Kinase |
| Protein Pathways | Acute myeloid leukemia, Adipocytokine signaling pathway, Apoptosis, B cell receptor signaling pathway, Chemokine signaling pathway, Chronic myeloid leukemia, Colorectal cancer, Endometrial cancer, ErbB signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, Glioma, Insulin signaling pathway, Jak-STAT signaling pathway, MAPK signaling pathway, Melanoma, mTOR signaling pathway, Neurotrophin signaling pathway, Non-small cell lung cancer, Pancreatic cancer, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Renal cell carcinoma, Small cell lung cancer, T cell receptor signaling pathway, Tight junction, Toll-like receptor signaling pathway, VEGF signaling pathway |
Reviews
Documents
| FAQs |
| SDS |
Resources
| Recombinant Protein Resources |
Other "AKT1" proteins (15)
| SKU | Description | Size | Price | |
|---|---|---|---|---|
| PH301850 | AKT1 MS Standard C13 and N15-labeled recombinant protein (NP_001014431) | 10 ug |
$3,360.00
|
|
| PH320257 | AKT1 MS Standard C13 and N15-labeled recombinant protein (NP_005154) | 10 ug |
$3,360.00
|
|
| PH320361 | AKT1 MS Standard C13 and N15-labeled recombinant protein (NP_001014432) | 10 ug |
$3,360.00
|
|
| LC401580 | Lyophilized AKT1 HEK293T cell transient overexpression lysate (as WB positive control) | 20 ug |
$206.00
|
|
| LC423056 | Lyophilized AKT1 HEK293T cell transient overexpression lysate (as WB positive control) | 20 ug |
$206.00
|
|
| LC423057 | Lyophilized AKT1 HEK293T cell transient overexpression lysate (as WB positive control) | 20 ug |
$206.00
|
|
| LC425358 | Lyophilized AKT1 HEK293T cell transient overexpression lysate (as WB positive control) | 20 ug |
$206.00
|
|
| LY401580 | Transient overexpression lysate of v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 1 (as WB positive control) | 100 ug |
$436.00
|
|
| LY423056 | Transient overexpression lysate of v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 3 (as WB positive control) | 100 ug |
$436.00
|
|
| LY423057 | Transient overexpression lysate of v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 2 (as WB positive control) | 100 ug |
$665.00
|
|
| LY425358 | Transient overexpression lysate of v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 2 (as WB positive control) | 100 ug |
$436.00
|
|
| TP301850 | Recombinant protein of human v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 3, 20 µg | 20 ug |
$737.00
|
|
| TP320361 | Recombinant protein of human v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 2, 20 µg | 20 ug |
$737.00
|
|
| TP700055 | Recombinant protein of human v-akt murine thymoma viral oncogene homolog 1 (AKT1) mutant (E17K), transcript variant 1 | 20 ug |
$900.00
|
|
| TP700060 | Recombinant protein of human v-akt murine thymoma viral oncogene homolog 1 (AKT1 mutant S473D), transcript variant 1, with C-terminal MYC/DDK tag, expressed in human cells, 20ug | 20 ug |
$900.00
|
|
Citations
Endogenous Cyclin D1 Promotes the Rate of Onset and Magnitude of Mitogenic Signaling via Akt1 Ser473 Phosphorylation
Chen, Jiao, Di Rocco et al
Cell Rep (2020) 32 (11), 108151 DOI: 10.1016/j.celrep.2020.108151
Chen, Jiao, Di Rocco et al
Cell Rep (2020) 32 (11), 108151 DOI: 10.1016/j.celrep.2020.108151
Cited by 15
AI Summary: In this study, purified Akt1 protein from OriGene (AKT1, CAT#TP320257) was used in cyclin D1 immune-precipitation kinase assays to investigate the role of cyclin D1 in regulating Akt1 activity and mitogenic signaling.
Snippet: … Other reagents Purified Akt1 used in the cyclin D1 immune-precipitation kinase assays was from OriGene, (AKT1, CAT#TP320257) or GST fusion proteins for pRB, which contains 2 CDK phosphorylation sites (Wang et al., 2006), Akt1 or Akt1-S473A, were generated in this laboratory as previously descri;Purified Akt1 used in the cyclin D1 immune-precipitation kinase assays was from OriGene, (AKT1, CAT#TP320257) or GST fusion proteins for pRB, which contains 2 CDK phosphorylation sites (Wang et al., 2006), Akt1 or Akt1-S473A, were generated in this laboratory as previously described (Wang et al., 2006). …
Inhibition of pressure-activated cancer cell adhesion by FAK-derived peptides
Zeng, Devadoss, Wang et al
Oncotarget (2017) 8 (58), 98051-98067 DOI: 10.18632/oncotarget.20556
Zeng, Devadoss, Wang et al
Oncotarget (2017) 8 (58), 98051-98067 DOI: 10.18632/oncotarget.20556
Cited by 8
Showing 1-2 of 2 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
